Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery
批准号:
10293947
负责人:
Carl Atkinson
金额:
$7.47万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-12-01 至 2020-12-31
关键词:
AcuteAddressAdhesionsAllograftingAntibodiesBlood VesselsBrain DeathBrain InjuriesBrain IschemiaCell Adhesion MoleculesCell CommunicationCellsClimactericCoagulation ProcessComplementComplement ActivationComplement InactivatorsComplexCyclosporineDataDepositionDevelopmentDoseEndothelial CellsEndotheliumEstheticsEventFaceGoalsGraft RejectionGraft SurvivalHindlimbImmuneImmune responseImmune systemImmunosuppressionImmunosuppressive AgentsImpairmentInflammationInjuryIntercellular adhesion molecule 1LeukocytesLifeLife ExpectancyLimb structureLinkLongevityMediatingMethodsModelingMuscleNatural regenerationNerveNerve DegenerationNerve RegenerationNervous System TraumaOrgan TransplantationP-SelectinPatientsPharmaceutical PreparationsPlatelet aggregationPlayPreventionProceduresProcessRecoveryRecovery of FunctionReperfusion InjuryResearchRestRiskRoleSavingsShapesSkinSolidStructureSystemT-LymphocyteTacrolimusTherapeuticTherapeutic immunosuppressionThrombosisTimeToxic effectTransplantationallograft rejectionbonecentral nervous system injurycomplement pathwaycomplement systemcongenicgraft functionhigh riskimprovedinhibitor/antagonistinnovationinsightisoimmunitynerve repairneurogenesisneurotoxicnovelnovel strategiesnovel therapeutic interventionperipheral nerve repairpost-transplantpreventresponsesuccesstooltransplant modeltransplantation therapy
中文摘要
项目概述:带血管蒂面部和肢体复合移植(VCA)移植(TX)不仅
这是可行的,但可能是恢复复杂结构美学和功能的一种更好的方法。尽管
最近在VCA TX的技术方面取得了长足的进步,但仍迫切需要开发新的
改善移植物功能和存活率的方法。然而,VCA会产生强烈的免疫反应,
而受者需要终身积极的免疫抑制来防止排斥反应。这会将收件人放置在
由于免疫抑制药物的高毒性,极大的风险和缩短的预期寿命。值得注意的是,
免疫抑制剂具有神经毒性,会损害神经再生,导致移植物质量下降。
功能恢复。考虑到这一点,而且因为VCA TX通常是改变生活的,但不是拯救生命的原则
研究的目标,也是这里讨论的一个目标,是开发新的战略,不仅促进
免疫抑制保留方案的使用还能使神经再生和移植物功能恢复。
虽然T细胞介导的排斥反应是移植物排斥反应的核心,但固体器官移植(SOT)的研究发现
移植后早期脑死亡(BD)损伤和缺血再灌注损伤(IRI),
作为同种免疫反应的关键启动子。BD和IRI在VCA中是否扮演类似的角色尚未得到
调查过了。BD和IRI都是VCA TX过程中不可避免的早期事件。我们建议调查
移植前和移植后的这些急性损伤在形成同种异体免疫反应和
其对移植物排斥反应、功能恢复和所需免疫抑制剂量的影响
防止T细胞介导的排斥反应。我们的工作假设是减少BD引起的损伤和IRI将减少
移植物的同种异体反应性和改善神经再生和修复,从而使更广泛的
这一改变人生的程序的应用。具体地说,我们将:1.描述一种新的目标定位方法
向VCA递送补体抑制剂,以及2.确定BD、C和早期同种异体移植损伤在
急性同种异体免疫反应、所需免疫抑制治疗的参数和功能后肢
恢复。这项提议的潜在影响是深远的,因为成功地减少了早期移植物损伤和
排斥在促进功能恢复的同时,有可能扩大对这种改变生活的利用
程序。此外,研究的治疗方法和获得的机械性见解可能会
对多个移植程序的影响。
英文摘要
Project Summary: Face and limb vascularized composite allograft (VCA) transplantation (Tx) is not only
feasible, but can be a superior method of restoring the aesthetics and function of complex structures. Despite
the recent strides made in the technical aspects of VCA Tx, there is still an urgent need to develop novel
approaches to improve graft function and survival. However, VCAs generate a strong immunological response,
and recipients require life-long aggressive immunosuppression to prevent rejection. This places the recipient at
substantial risk and shortened life expectancy due to the high toxicity of immunosuppressive drugs. Significantly,
immunosuppressives are neurotoxic and can impair neuroregeneration, leading to poorer graft
functional recovery. Given this, and because VCA Tx is usually life-changing, but not lifesaving, a principle
research goal, and one that is addressed herein, is the development of novel strategies that not only facilitate
the use of immunosuppressive sparing regimes but also enable neurogenesis and graft functional recovery.
While T cell-mediated rejection is central to graft rejection, studies in solid organ transplant (SOT) have identified
the early post-transplant graft injuries of brain death (BD) induced injury and ischemia reperfusion injury (IRI),
as key primers of the alloimmune response. Whether BD and IRI play similar roles in VCA has not been
investigated. Both BD and IRI are unavoidable early events in the VCA Tx process. We propose to investigate
the role of these acute pre and post-transplant injuries on the shaping of an alloimmune response and the
consequences thereof on graft rejection, functional recovery, and dose of immunosuppressive required to
prevent T-cell mediated rejection. Our working hypothesis is that reducing BD induced injury and IRI will reduce
graft alloresponsiveness and improve nerve regeneration and repair, thus enabling the more widespread
application of this life-changing procedure. Specifically, we will: 1. Characterize a novel targeting approach for
delivery of a complement inhibitor to VCAs, and 2. Determine the role of BD, C and early allograft injury on an
acute alloimmune response, the parameters of required immunosuppressive therapy, and functional hindlimb
recovery. The potential impact of this proposal is far-reaching as success in reducing early graft injury and
rejection, while promoting functional recovery, has the potential to expand the utilization of this life changing
procedure. Furthermore, the therapeutic approaches investigated and mechanistic insights gained will likely have
implications for multiple transplantation procedures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation
-
批准号:10481101
-
项目类别:
-
资助金额:$41.85万
-
财政年份:2022
-
负责人:Carl Atkinson
-
依托单位:
The Complement System and Cancer Cachexia
-
批准号:10537488
-
项目类别:
-
资助金额:$47.71万
-
财政年份:2022
-
负责人:Carl Atkinson
-
依托单位:
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation
-
批准号:10693272
-
项目类别:
-
资助金额:$40.54万
-
财政年份:2022
-
负责人:Carl Atkinson
-
依托单位:
The Complement System and Cancer Cachexia
-
批准号:10674024
-
项目类别:
-
资助金额:$47.71万
-
财政年份:2022
-
负责人:Carl Atkinson
-
依托单位:
Complement driven innate and adaptive autoreactivity in lung transplantation
-
批准号:10363208
-
项目类别:
-
资助金额:$44.5万
-
财政年份:2021
-
负责人:Carl Atkinson
-
依托单位:
Complement driven innate and adaptive autoreactivity in lung transplantation
-
批准号:10228849
-
项目类别:
-
资助金额:$14.49万
-
财政年份:2020
-
负责人:Carl Atkinson
-
依托单位:
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis
-
批准号:9886648
-
项目类别:
-
资助金额:$42.6万
-
财政年份:2020
-
负责人:Carl Atkinson
-
依托单位:
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis
-
批准号:10355859
-
项目类别:
-
资助金额:$43.35万
-
财政年份:2020
-
负责人:Carl Atkinson
-
依托单位:
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis
-
批准号:10094187
-
项目类别:
-
资助金额:$45.85万
-
财政年份:2020
-
负责人:Carl Atkinson
-
依托单位:
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery
-
批准号:10399007
-
项目类别:
-
资助金额:$33.78万
-
财政年份:2020
-
负责人:Carl Atkinson
-
依托单位:
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy
-
批准号:10187511
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2017
-
负责人:Carl Atkinson
-
依托单位:
The Role of Complement in the Pathogenesis of Emphysema
-
批准号:7783443
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2010
-
负责人:Carl Atkinson
-
依托单位:
The Role of Complement in the Pathogenesis of Emphysema
-
批准号:8033680
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2010
-
负责人:Carl Atkinson
-
依托单位:
The Role of Complement in the Pathogenesis of Emphysema
-
批准号:8432817
-
项目类别:
-
资助金额:$34.75万
-
财政年份:2010
-
负责人:Carl Atkinson
-
依托单位:
The Role of Complement in the Pathogenesis of Emphysema
-
批准号:8616088
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2010
-
负责人:Carl Atkinson
-
依托单位:
The Role of Complement in the Pathogenesis of Emphysema
-
批准号:8230683
-
项目类别:
-
资助金额:$36.51万
-
财政年份:2010
-
负责人:Carl Atkinson
-
依托单位:
海外基金